Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study

BACKGROUND: Vedolizumab has been shown to induce clinical remission in patients with active ulcerative colitis. Treatment with anti-integrin vedolizumab leads to clinical remission in 16.9% and clinical response in 47.1% of cases after 6 weeks. However, in clinical practice, no decision to discontin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cording, Jimmi, Blömacher, Margit, Wiebe, Berit Inga, Langhorst, Jost, Kucharzik, Torsten, Sturm, Andreas, Schreiber, Stefan, Helwig, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874801/
https://www.ncbi.nlm.nih.gov/pubmed/31702563
http://dx.doi.org/10.2196/14335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874801/
https://www.ncbi.nlm.nih.gov/pubmed/31702563
http://dx.doi.org/10.2196/14335

Ejemplares similares